HDL Therapeutics, Inc. With an FDA approved therapy, HDL Therapeutics aims to reduce coronary atheroma in a rare cardiovascular disease. Their unique culture encourages viewing patient treatment from a different perspective, seeking disruptive scientific breakthroughs for better patient outcomes.

The company's can-do attitude fuels the creation of real solutions to health challenges. HDL Therapeutics represents the combined expertise of top talents from the pharmaceutical, biotechnology, and medical device industries. Co-founders Michael Matin, CEO and Chairman of the Board, and Dr.

Bryan Brewer, Chief Scientific Officer, bring extensive experience with large pharmaceutical organizations, blockbuster product launches, and breakthrough research. Striving to make a significant impact, HDL Therapeutics is at the forefront of developing cutting-edge therapies for various diseases including cardiovascular, neurodegenerative, autoimmune, viral, and peripheral vascular diseases. Their mission is to fill a critical gap in treatment options for patients with severe atherosclerotic disease, by utilizing their breakthrough therapy that harnesses the power of HDL to reverse atherosclerosis